PMID- 29681802
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1662-5137 (Print)
IS  - 1662-5137 (Electronic)
IS  - 1662-5137 (Linking)
VI  - 12
DP  - 2018
TI  - Expression and Function of Chemokines CXCL9-11 in Micturition Pathways in 
      Cyclophosphamide (CYP)-Induced Cystitis and Somatic Sensitivity in Mice.
PG  - 9
LID - 10.3389/fnsys.2018.00009 [doi]
LID - 9
AB  - Changes in urinary bladder function and somatic sensation may be mediated, in 
      part, by inflammatory changes in the urinary bladder including the expression of 
      chemokines. Male and female C57BL/6 mice were treated with cyclophosphamide (CYP; 
      75 mg/kg, 200 mg/kg, i.p.) to induce bladder inflammation (4 h, 48 h, chronic). 
      We characterized the expression of CXC chemokines (CXCL9, CXCL10 and CXCL11) in 
      the urinary bladder and determined the effects of blockade of their common 
      receptor, CXCR3, at the level urinary bladder on bladder function and somatic 
      (hindpaw and pelvic) sensation. qRT-PCR and Enzyme-Linked Immunoassays (ELISAs) 
      were used to determine mRNA and protein expression of CXCL9, CXCL10 and CXCL11 in 
      urothelium and detrusor. In urothelium of female mice treated with CYP, CXCL9 and 
      CXCL10 mRNA significantly (p </= 0.01) increased with CYP treatment whereas CXC 
      mRNA expression in the detrusor exhibited both increases and decreases in 
      expression with CYP treatment. CXC mRNA expression urothelium and detrusor of 
      male mice was more variable with both significant (p </= 0.01) increases and 
      decreases in expression depending on the specific CXC chemokine and CYP 
      treatment. CXCL9 and CXCL10 protein expression was significantly (p </= 0.01) 
      increased in the urinary bladder with 4 h CYP treatment in female mice whereas 
      CXC protein expression in the urinary bladder of male mice did not exhibit an 
      overall change in expression. CXCR3 blockade with intravesical instillation of 
      AMG487 (5 mg/kg) significantly (p </= 0.01) increased bladder capacity, reduced 
      voiding frequency and reduced non-voiding contractions in female mice treated 
      with CYP (4 h, 48 h). CXCR3 blockade also reduced (p </= 0.01) hindpaw and pelvic 
      sensitivity in female mice treated with CYP (4 h, 48 h). CXC chemokines may be 
      novel targets for treating urinary bladder dysfunction and somatic sensitization 
      resulting from urinary bladder inflammation.
FAU - Guo, Michael
AU  - Guo M
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Chang, Phat
AU  - Chang P
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Hauke, Eric
AU  - Hauke E
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Girard, Beatrice M
AU  - Girard BM
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Tooke, Katharine
AU  - Tooke K
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Ojala, Jacqueline
AU  - Ojala J
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Malley, Susan M
AU  - Malley SM
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Hsiang, Harrison
AU  - Hsiang H
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
FAU - Vizzard, Margaret A
AU  - Vizzard MA
AD  - Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine, 
      The University of Vermont, Burlington, VT, United States.
LA  - eng
GR  - R25 NS090623/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20180406
PL  - Switzerland
TA  - Front Syst Neurosci
JT  - Frontiers in systems neuroscience
JID - 101477946
PMC - PMC5897511
OTO - NOTNLM
OT  - BPS/IC
OT  - CXC chemokines
OT  - CXCR3
OT  - ELISAs
OT  - cystometry
OT  - urinary bladder
EDAT- 2018/04/24 06:00
MHDA- 2018/04/24 06:01
PMCR- 2018/01/01
CRDT- 2018/04/24 06:00
PHST- 2018/01/30 00:00 [received]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/04/24 06:00 [entrez]
PHST- 2018/04/24 06:00 [pubmed]
PHST- 2018/04/24 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fnsys.2018.00009 [doi]
PST - epublish
SO  - Front Syst Neurosci. 2018 Apr 6;12:9. doi: 10.3389/fnsys.2018.00009. eCollection 
      2018.